ReviewCurrent urology reports2026
A Comprehensive Review of Minimally Invasive Surgical Therapies for Voiding Dysfunction in Benign Prostatic Hyperplasia: Past Failures, Contemporary Successes and Future Innovations.
Review in Current urology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTreatments for voiding dysfunction secondary to benign prostatic hyperplasia (BPH) have evolved greatly but also attempted to recapitulate existing ideas. This review will detail the MISTs for BPH through three temporal lenses: past failures and their lessons, contemporary therapies with evidence bases and emerging technologies that are potential futures for minimally invasive BPH treatment. RECENT
findingsNewer minimally invasive surgical therapies (MISTs) either occupy a new technological niche or refine concepts used by earlier, unsuccessful BPH treatments. Historical permanent stents, balloon dilation, prostatic injection therapies, transurethral needle ablation, and transurethral microwave thermotherapy were limited by complications, inconsistent objective improvement, or high retreatment rates. Contemporary options, including prostatic urethral lift, water-vapor thermal therapy, and drug-coated balloon dilation, demonstrate improved symptom and flow outcomes in selected patients, while temporary nitinol devices and histotripsy continue to evolve. Contemporary devices frequently revisit earlier mechanical, thermal, or dilation-based approaches. Improved materials and delivery systems may reduce prior limitations, but they do not eliminate the need to demonstrate durable efficacy, acceptable retreatment rates, preservation of sexual function, and appropriate patient selection through high-quality long-term studies.
Indexed as
Identifiers
42669738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.